Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model

Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model

Patients with Parkinson’s disease (PD) have impaired insulin signaling in the brain. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), can re-sensitize insulin signaling. In a recent phase II clinical trial, the first GLP-1 mimic, ex...

Full description

Bibliographic Details
Main Authors: Ling-Yu Zhang, Qian-Qian Jin, Christian Hölscher, Lin Li
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Neural Regeneration Research
Subjects:
neurodegenerative disease; parkinson’s disease; insulin resistance; inflammation; glp-1/gip receptor unimolecular co-agonist
Online Access:http://www.nrronline.org/article.asp?issn=1673-5374;year=2021;volume=16;issue=8;spage=1660;epage=1670;aulast=Zhang

Internet

http://www.nrronline.org/article.asp?issn=1673-5374;year=2021;volume=16;issue=8;spage=1660;epage=1670;aulast=Zhang

Similar Items